

Closer to the market

Trading UBS leverage products on Swiss DOTS **from 8.00 am to 10.00 pm**

For marketing purposes only

UBS offers a large selection of leverage products on Swiss DOTS and enables clients of Swissquote Bank to trade products at attractive conditions. Investors can profit from various advantages.

I. Wide range of products

On the trading platform Swiss DOTS (short form for Swiss Derivatives OTC Trading System) you will find more than 25,000 UBS Warrants, Mini Futures and Turbo Warrants on a large universe of underlying assets. UBS products on Swiss DOTS are always settled in cash and thus no underlying assets are delivered.

II. Extended trading times

All UBS products are traded on exchange trading days from 8.00 am until 10.00 pm. Products on equities can be removed from trading on a temporary basis during any relevant auctions in the underlying or corporate action. On public holidays, Swiss DOTS generally has the same trading hours as the stock exchange on which the underlying values are traded. Times might differ in particular cases. Products based on currency pairs and commodities generally have the same trading hours as EU equities.

III. Attractive prices

Trading quality is a high priority for Swiss DOTS: UBS leverage products are rounded to three decimal places. In addition, tight bid-ask spreads, i.e. small differences between the buying and selling rates, ensure low transaction costs for the product. The pricing for large trading volumes generally allows liquid and problem-free trading even for high numbers of units.

IV. Secure trading

If for any reason a mistrade (incorrect trade concluded) should occur, clear mistrade rules are triggered immediately. A buying or selling trade is declared to be a mistrade if it is concluded at a price that deviates significantly from the market price that was valid at the relevant time of the trade. This means that it can be guaranteed that the UBS product range is always traded at fair conditions. This is monitored both by Swissquote and the issuers.

Your most important advantages at a glance

- **Large product offering**
Investors can currently choose from more than 25,000 UBS Warrants, Mini Futures and Turbo Warrants.
- **Wide range of underlyings**
Investors can trade UBS leverage products on more than 200 underlyings based on equities, indices, commodities and currency pairs.
- **Extended trading times**
All products can be traded 14 hours a day from 8.00 am to 10.00 pm. on exchange trading days.
- **Simple fee structure**
Depending on the trade currency a fee of 9 CHF, EUR or USD is charged per trade.
- **Narrow spreads**
Bid and ask prices of up to three decimal places ensure low overall transaction costs.
- **Multiple order types available**
In addition to market orders, limit, stop limit, trailing stops and One-Cancels-Other (OCO) orders are also available.

More information:

ubs.com/swissdots

swissquote.ch/swissdots

 Swiss DOTS

V. Efficient order processing

Different order types are supported by Swiss DOTS. Swissquote ensures that the transactions are concluded in accordance with the order type. The client can choose between market order, limit order, stop-loss order, and stop-limit order. The stop levels are monitored continuously on the basis of the UBS bid-ask rates and executed immediately once the limit is reached. There is also the option of a quote request, which is answered by UBS trading desk in real time

VI. More than 200 underlyings from the international equity universe available

Switzerland	Orascom	Commerzbank	USA	Johnson & Johnson
ABB	Panalpina	Continental	3M	JPMorgan Chase
Actelion	Pargesa	Credit Agricole	Activision Blizzard	MasterCard
Adecco	Partners Group	Daimler	Adobe Systems	McDonald's
AFG	PSP	Deutsche Bank	Alibaba	Microsoft
AMS	Richemont	Deutsche Börse	Alphabet	Netflix
Aryzta	Rieter	Deutsche Lufthansa	Altria	Newmont Mining
Autoneum	Roche	Deutsche Post	Amazon.com	Nike
Baloise	Schindler	Deutsche Telekom	AMD	NVIDIA
Barry Callebaut	Schmolz + Bickenbach	ElringKlinger	American Express	Oracle
Basilea	SFS Holding	Eni	Amgen	PayPal
BB Biotech	SGS	Fraport	Apple	Pfizer
BKW	Sika	Fresenius	Autodesk	Philip Morris
Bucher Industries	Sonova	Fresenius Medical Care	Baidu Inc	Qualcomm
Burckhardt Compression	Straumann	Fuchs Petrolub	Bank of America	Rambus
Cembra Money Bank	Sulzer	GEA Group	Barrick Gold	Schlumberger
Clariant	Sunrise	Heidelberg Cement	Berkshire Hathaway	Starbucks
COSMO	Swatch	Henkel	Boeing	Tesla Motors
Credit Suisse	Swiss Life	Infineon	Caterpillar	The Priceline Group
Dialog	Swiss Prime Site	ING	Celgene Corporation	Transocean
DKSH	Swiss Re	K+S	Chesapeake Energy	Twitter Inc.
dorma + kaba	Swisscom	Kloekner & Co.	Chevron	Union Pacific
Dufry	Syngenta	Lanxess	Cisco Systems	Vale
EFG International	Temenos	Linde	Citigroup	Visa
EMMI AG	U-Blox	LVMH	ConocoPhillips	Wal-Mart Stores
EMS Chemie	UBS	Merck	Dow Chemical	Walt Disney
Flughafen Zurich	Valora	Metro	eBay	Whole Foods Market
Forbo	VAT	Muenchener Rueck	Electronic Arts	Yahoo!
Galenica	Vontobel	Orange	Eli Lilly	
GAM Holding	Zurich Insurance	Peugeot	Exxon Mobil	Indices
Geberit		Philips	Facebook	DAX™
Georg Fischer	Europe	Porsche	Ferrari	Dow Jones™
Givaudan	Aareal Bank	Renault	First Solar	Euro STOXX 50™
Helvetia	adidas	Royal Dutch Shell	Ford	Nasdaq 100™
Julius Baer	Airbus	RWE	Freeport McMoRan	S&P 500™
Kudelski	Allianz	Sanofi	General Electric	SMI™
Kuehne + Nagel	Anheuser-Busch	SAP	General Mills	
LafargeHolcim	ArcelorMittal	Schneider Electric	General Motors	
Leonteq	ASM Lithography	Siemens	Gilead	
Lindt & Spruengli	AXA	Société Générale	Goldman Sachs	
Logitech	BASF	ThyssenKrupp	Groupon	
Lonza	Bayer	Total	Halliburton	
Meyer Burger	Beiersdorf	UniCredit	Hewlett Packard	
Nestlé	Bilfinger	Volkswagen	Home Depot	
Novartis	BMW	Wacker Chemie	IBM	
OC Oerlikon	BNP Paribas	Zalando	Intel	

UBS KeyInvest

Hotline: +41 44 239 76 76

Email: keyinvest@ubs.com

ubs.com/keyinvest

Disclaimer

This information is communicated by UBS AG and/or its affiliates ("UBS"). UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the product to which this document relates (the "Product"). UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in this document. UBS's trading and/or hedging activities related to the Product may have an impact on the price of the underlying asset and may affect the likelihood that any relevant barrier is crossed. UBS has policies and procedures designed to minimise the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available. In certain circumstances UBS sells the Product to dealers and other financial institutions at a discount to the issue price or rebates to them for their own account some proportion of the issue price. Further information is available on request. Structured products are complex and may involve a high risk of loss. Prior to purchasing the Product you should consult with your own legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of the Product) based upon your own judgement and advice from those advisers you consider necessary. Save as otherwise expressly agreed in writing, UBS is not acting as your financial adviser or fiduciary in relation to the Product. Unless stated otherwise in this document, (i) this document is for information purposes only and should not be construed as an offer, personal recommendation or solicitation to purchase the Product and should not be treated as giving investment advice, and (ii) the terms of any investment in the Product will be exclusively subject to the detailed provisions, including risk considerations, contained in the information memorandum, prospectus or other issuer documentation for the issue of the Product. UBS makes no representation or warranty relating to any information herein which is derived from independent sources. This document shall not be copied or reproduced without UBS's prior written permission. No action has been or will be taken in any jurisdiction that would permit a public offering of the Product, save where explicitly stated in the issuer documentation. The Product must be sold in accordance with all applicable selling restrictions in the jurisdictions in which it is sold. This material contains data derived as a result of backtesting of data and is provided by UBS in good faith using our standard methodology for information of this kind. That methodology relies on proprietary models, empirical data, assumptions and such other information that we believe to be accurate and reasonable. We make, however, no representation as to the accuracy, completeness or appropriateness of such methodology and accept no liability for your use of the Information. Specifically, there is no assurance that other banks or brokers would derive the same results for the backtest period. © UBS 2015. All rights reserved.